ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2013
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Targeting Protein Aggregates with Natural Products: An Optional Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2023Pooled it
- DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Pooled it
- A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease.Journal of neurology · 2026Review
- Insulin signaling disruption exacerbates memory impairment and seizure susceptibility in an epilepsy model with Alzheimer's disease-like pathology.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Article
- Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.Science China. Life sciences · 2021Review
- An Overview of Astrocyte Responses in Genetically Induced Alzheimer's Disease Mouse Models.Cells · 2020Review
- Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.Molecular neurobiology · 2019Article
- A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation.Dementia and neurocognitive disorders · 2019Review
- Targeting Autophagy for the Treatment of Alzheimer's Disease: Challenges and Opportunities.Frontiers in molecular neuroscience · 2019Article
- Peptides as Potential Therapeutics for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2018Review
- Article
- Increased expression of Myc-interacting zinc finger protein 1 in APP/PS1 mice.Experimental and therapeutic medicine · 2017Article
- Towards Personalized Intervention for Alzheimer's Disease.Genomics, proteomics & bioinformatics · 2016Review
- The Role of Reelin Signaling in Alzheimer's Disease.Molecular neurobiology · 2016Review
- Tau imaging in neurodegenerative diseases.European journal of nuclear medicine and molecular imaging · 2016Review
- A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.Molecular neurodegeneration · 2016Article
- AlzBase: an Integrative Database for Gene Dysregulation in Alzheimer's Disease.Molecular neurobiology · 2016Article
- AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons.Oxidative medicine and cellular longevity · 2016Article
- Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?Alzheimer's & dementia (Amsterdam, Netherlands) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.